By Sina Rezvan Pathology labs rarely grow in neat, predictable increments. Volume shifts don’t arrive on a schedule or follow a clean upward trajectory. They emerge from new hospital partnerships, outreach expansion, the addition of subspecialty services, health system consolidation, or unexpected staffing changes that alter capacity almost overnight. What looks stable one quarter can […]
By Elizabeth Earin Digital pathology initiatives rarely slow down because the technology does not work. More often, they slow down because the evaluation shifts from broad strategy to detailed operational review. Early conversations focus on long-term goals such as improving turnaround time, enabling collaboration across locations, and modernizing workflow infrastructure. There is general agreement that digital capability is becoming foundational,
By Elizabeth Earin Digital pathology transformation doesn’t stall because of scanners or AI. It stalls because of routing. Too often, labs focus on image quality or algorithm performance while leaving case distribution logic unchanged. In an analog world, routing was defined by physical slide movement. In a digital environment, it becomes a strategic architecture decision — determining who sees
Case Routing Is the Real Lever in Digital Pathology Read More »
By Sina Rezvan Most digital pathology IMS platforms look similar in a demo. Slides load. Cases open. Reports export. At first glance, the functionality appears comparable. The differences emerge later when volume increases, sites expand, turnaround times tighten, or AI becomes part of daily workflow. That’s when architecture starts to matter. Choosing a digital pathology IMS isn’t just about enabling digital sign-out. It’s about selecting infrastructure that will scale with your lab over
How to Evaluate a Digital Pathology IMS: The Criteria That Matters Most Read More »
By Lisa-Jean Clifford Many laboratories evaluating AI in digital pathology ask the wrong first question: Does the model work? Accuracy matters — but most AI initiatives don’t stall because of performance metrics. They stall because the technology disrupts the diagnostic workflow pathologists rely on every day. If AI requires switching platforms, adding manual steps, or reworking case workflows, it becomes
January 4, 2022 – Hamburg, Germany, based Mindpeak and Spokane, WA, based Gestalt Diagnostics have achieved a major success on their way to improve patient care with Digital Pathology and Artificial Intelligence (AI). US based BioReference Laboratories, Inc., an OPKO Health company and one of the largest laboratories in the United States with 19 million patients
Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution. PathFlow®, to support its pathology business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. Under the agreement, Gestalt is partnering with Leica Biosciences, which provides